55E3F1FB-D55D-42F8-A9E1-7828F7BFF595
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.520367936925098
- age_years
- 66
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.669
- MYC_TARGETS_V1+0.643
- G2M_CHECKPOINT+0.641
- MYC_TARGETS_V2+0.622
- UNFOLDED_PROTEIN_RESPONSE+0.561
- MTORC1_SIGNALING+0.550
- DNA_REPAIR+0.525
- INTERFERON_ALPHA_RESPONSE+0.491
- ANGIOGENESIS+0.467
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.459
Top 10 suppressed
- KRAS_SIGNALING_DN-0.445
- PANCREAS_BETA_CELLS-0.242
- MYOGENESIS-0.234
- SPERMATOGENESIS-0.191
- BILE_ACID_METABOLISM-0.122
- ESTROGEN_RESPONSE_EARLY-0.074
- ESTROGEN_RESPONSE_LATE-0.072
- XENOBIOTIC_METABOLISM-0.002
- HEME_METABOLISM+0.016
- APICAL_SURFACE+0.048
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EB8F7B74-694A-4F9F-9C0B-F04006033CA4 | — | — | 0.971 |
| 2 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.971 |
| 3 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.970 |
| 4 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.966 |
| 5 | E317AD4C-E877-499A-B108-2F39A40D1682 | — | — | 0.962 |
| 6 | A21476BD-0550-4D87-80EA-6E1454E0896D | — | — | 0.961 |
| 7 | 52F6F0A9-8D2D-49BC-9B49-E20E5E53561C | — | — | 0.961 |
| 8 | SRR934861 | — | — | 0.960 |
| 9 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.960 |
| 10 | C5C8713B-05C1-4C5C-8685-2A546B99BA50 | — | — | 0.960 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.669 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.643 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.641 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.622 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.561 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.550 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.525 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.491 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.467 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.459 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.432 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.415 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.405 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.389 | Inavolisib | — uncovered |
| HYPOXIA | 0.374 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.368 | Inavolisib | — uncovered |
| APOPTOSIS | 0.356 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.350 | Inavolisib | — uncovered |